Regulation of interferon pathway in 2-methoxyestradiol-treated osteosarcoma cells

Fritz Wimbauer1,2†, Caihong Yang1,3†, Kristen L Shogren1, Minzhi Zhang1, Ribu Goyal1, Scott M Riester1, Michael J Yaszemski1,2 and Avudaiappan Maran1,2*

Abstract
Background: Osteosarcoma is a bone tumor that often affects children and young adults. Although a combination of surgery and chemotherapy has improved the survival rate in the past decades, local recurrence and metastases still develop in 40% of patients. A definite therapy is yet to be determined for osteosarcoma. Anti-tumor compound and a metabolite of estrogen, 2-methoxyestradiol (2-ME) induces cell death in osteosarcoma cells. In this report, we have investigated whether interferon (IFN) pathway is involved in 2-ME-induced anti-tumor effects in osteosarcoma cells.

Methods: 2-ME effects on IFN mRNA levels were determined by Real time PCR analysis. Transient transfections followed by reporter assays were used for investigating 2-ME effects on IFN-pathway. Western blot analyses were used to measure protein and phosphorylation levels of IFN-regulated eukaryotic initiation factor-2 alpha (eIF-2α).

Results: 2-ME regulates IFN and IFN-mediated effects in osteosarcoma cells. 2-ME induces IFN gene activity and expression in osteosarcoma cells. 2-ME treatment induced IFN-stimulated response element (ISRE) sequence-dependent transcription and gamma-activated sequence (GAS)-dependent transcription in several osteosarcoma cells. Whereas, 2-ME did not affect IFN gene and IFN pathways in normal primary human osteoblasts (HOB). 2-ME treatment increased the phosphorylation of eIF-2α in osteosarcoma cells. Furthermore, analysis of osteosarcoma tissues shows that the levels of phosphorylated form of eIF-2α are decreased in tumor compared to normal controls.

Conclusions: 2-ME treatment triggers the induction and activity of IFN and IFN pathway genes in 2-ME-sensitive osteosarcoma tumor cells but not in 2-ME-resistant normal osteoblasts. In addition, IFN-signaling is inhibited in osteosarcoma patients. Thus, IFN pathways play a role in osteosarcoma and in 2-ME-mediated anti-proliferative effects, and therefore targeted induction of IFN signaling could lead to effective treatment strategies in the control of osteosarcoma.

Keywords: 2-Methoxyestradiol, osteosarcoma, Interferon, ISRE, GAS

Background
Osteosarcoma is the most common malignant primary bone tumor in children and adolescents. It is the 6th leading cancer in children under 15. Osteosarcoma accounts for 2.4% of all malignancies in pediatric patients and approximately 20% of all bone cancers [1,2]. Current standard treatment is to use neoadjuvant chemotherapy followed by surgical resection. Although a combination of surgery and chemotherapy has led to improved survival rate, a definite therapy is yet to be determined for this disease. 2-Methoxyestradiol (2-ME), which acts as a potential anti-tumor agent in several types of cancer, has been shown to block cell growth and induce apoptosis in osteosarcoma cells [3-8].

IFNs are a family of cytokines synthesized and secreted by most cell types that elicit pleiotropic biological effects [9]. Three main classes of IFNs namely, α, β and γ have been identified and classified as type I (α, β) and type II (γ). IFNs which induce anti-viral, anti-angiogenic, anti-proliferative, anti-cancer effects and immune modulatory effects, have been shown to block the progression of
cancer in vitro and in vivo [9-11]. The biological effects of IFNs are mediated through IFN-regulated genes. Three major IFN-regulated pathways involving RNA-dependent protein kinase (PKR)/the eukaryotic initiation factor (eIF)-2a system, 2-5A synthetase/RNase L system and Janus Kinase (JAK)/signal transducer and activator of transcription (STAT) system have been identified [9]. PKR/eIF2a system mainly mediates type I IFN effects and the protein synthesis factor eIF-2a functions as the effector of PKR-induced effects in this pathway [9]. IFN’s role in maintenance therapy has been investigated in osteosarcoma and other cancers. Several studies have demonstrated that IFNs block osteosarcoma growth in patients, animal models, and in cultured cells [10,12]. IFNα has been studied as a maintenance therapy after post-operative chemotherapy with cisplatin, doxorubicin and methotrexate [12,13]. In murine model of osteosarcoma, IFNα reduces the tumor growth and the metastatic nodules in the lungs [14]. IFNβ has been shown to block the growth of osteosarcoma cells in vitro. In addition IFN enhances antitumor activity of chemotherapeutic agents [15,16]. We have demonstrated that the anti-growth effects of 2-ME are accompanied by increases in IFN mRNA levels in osteosarcoma cells [5]. In this report, we have investigated the regulation and association of IFN pathways in 2-ME-mediated effects in osteosarcoma cells.

Methods
Primary human osteoblast (HOB) cells
HOB cells were established from cancellous bone obtained as surgical waste material from orthopedic surgeons, legal and administrative team members including pathologists, oncologists, orthopedic surgeons, legal and administrative team members. The tumor tissues were obtained through surgical resection. The normal muscle tissues collected in this study were normal muscle tissues adjacent to osteosarcoma tissues occurring within the same patient. The histology was reviewed by fellowship-trained cancer in vitro and in vivo [9-11]. The biological effects of IFNs are mediated through IFN-regulated genes. Three major IFN-regulated pathways involving RNA-dependent protein kinase (PKR)/the eukaryotic initiation factor (eIF)-2a system, 2-5A synthetase/RNase L system and Janus Kinase (JAK)/signal transducer and activator of transcription (STAT) system have been identified [9]. PKR/eIF2a system mainly mediates type I IFN effects and the protein synthesis factor eIF-2a functions as the effector of PKR-induced effects in this pathway [9]. IFN’s role in maintenance therapy has been investigated in osteosarcoma and other cancers. Several studies have demonstrated that IFNs block osteosarcoma growth in patients, animal models, and in cultured cells [10,12]. IFNα has been studied as a maintenance therapy after post-operative chemotherapy with cisplatin, doxorubicin and methotrexate [12,13]. In murine model of osteosarcoma, IFNα reduces the tumor growth and the metastatic nodules in the lungs [14]. IFNβ has been shown to block the growth of osteosarcoma cells in vitro. In addition IFN enhances antitumor activity of chemotherapeutic agents [15,16]. We have demonstrated that the anti-growth effects of 2-ME are accompanied by increases in IFN mRNA levels in osteosarcoma cells [5]. In this report, we have investigated the regulation and association of IFN pathways in 2-ME-mediated effects in osteosarcoma cells.

Methods
Primary human osteoblast (HOB) cells
HOB cells were established from cancellous bone obtained as surgical waste material from orthopedic surgeons, legal and administrative team members including pathologists, oncologists, orthopedic surgeons, legal and administrative team members. The tumor tissues were obtained through surgical resection. The normal muscle tissues collected in this study were normal muscle tissues adjacent to osteosarcoma tissues occurring within the same patient. The histology was reviewed by fellowship-trained
musculoskeletal pathologists to confirm proper diagnosis. After collection, the tissues were stored at -70°C until processed for protein analysis.

Protein analysis and western blot hybridization
Protein analysis was carried out as described [4]. Briefly, vehicle- and 2-ME-treated cells were harvested and lysed by suspending in cell lysis buffer. After centrifugation at 10,000 x g for 10 min, the supernatant was collected, and the protein concentration was determined by Bradford protein assay. Normal and tumor tissues obtained from patients according to the IRB-approved protocol were homogenized in lysis buffer and the protein concentration was determined. Cytoplasmic extract containing protein (60 μg) was analyzed by Western blot hybridization using anti-phospho-eIF-2α (1: 1000 dilution), anti-eIF-2α (1: 3000 dilution) and anti-glyceroldehyde 3-phosphate dehydrogenase (GAPDH) (1: 5000 dilution) antibodies (Santa Cruz Biotechnology, Santa Cruz, CA). The expression levels of proteins on the western blots were quantitated using densitometer and PD Quest 7.4.0 software (BioRad, Hercules, CA).

Statistical analysis
All values are expressed as means ± standard error. The data is representative of three independent experiments. Significant differences between groups were determined by Fisher’s protected least significant difference post hoc test for multiple-group comparisons following detection of significance by one-way analysis of variance (ANOVA). P < 0.005 was considered statistically significant.

Results
2-ME effect on IFN gene in osteosarcoma cells
We have demonstrated previously that 2-ME treatment induces IFN mRNA levels in MG63 osteosarcoma cells. In order to determine whether 2-ME treatment affects IFN mRNA levels in osteosarcoma cell types with different metastatic potentials, we have carried out Real time PCR and measured on IFN mRNA levels in MG63 and 143B osteosarcoma cells. 2-ME treatment induced IFNα and β mRNA levels in MG63 osteosarcoma cells (Figure 1A and 1B). IFNα mRNA levels were increased by 2.7-, 2-, 3- and 4.5-fold, and IFNβ mRNA levels were increased by 3-, 2-, 4- and 7.8-fold at 4, 8, 16 and 24 h, respectively. 2-ME increased IFNα mRNA levels at 16 h by 8-fold compared to vehicle control but did not have any effect at other time points (8 and 24 h) analyzed (Figure 1C). 2-ME treatment induced IFNα and β mRNA levels in 143B osteosarcoma cells (Figure 1C and 1D). 2-ME increased IFNα mRNA levels at 16 h by 8-fold compared to vehicle control but did not have any effect at other time points (8 and 24 h) analyzed (Figure 1C). 2-ME treatment increased IFNβ mRNA levels at 8 and 24 h by 2- and 3.5-fold and did not affect at 16 h compared to the vehicle controls (Figure 1D). Our results show that 2-ME does not regulate IFNα and β mRNA levels in normal osteoblasts (Figure 1E and 1-F).

In order to determine whether 2-ME has a direct effect on IFN genes, we have investigated the effect of 2-ME on IFNβ gene-driven luciferase activity by transient transfection assays in human osteosarcoma cells. Relative to vehicle control, 2-ME treatment stimulated the luciferase activity by 9- and 4.5-fold in MG63 and 143B osteosarcoma cells, respectively (Figure 2). Our results show that 2-ME does not regulate IFNβ gene-driven luciferase activity in normal HOB cells (Figure 2).

2-ME effects on IFN-dependent effects in osteosarcoma cells
To determine whether 2-ME treatment induces IFN-dependent transcription, we have tested the effect of 2-ME treatment on interferon-stimulated response element (ISRE) and γ-activated sequence (GAS). 2-ME actions on luciferase reporter constructs driven by ISRE and GAS sequences were determined by transient transfection assays in human osteosarcoma cells. 2-ME treatment induced IFN-stimulated response element (ISRE) sequence-dependent transcription by 4-, 8-, 9- and 4.5-fold in MG63, 143B, KHOS and HOS cells, respectively (Figure 3). 2-ME stimulated gamma-activated (GAS) sequence-dependent transcriptions by 4-, 5- and 10-fold in MG63, 143B and KHOS cells, respectively (Figure 4). 2-ME, however, showed no effect on GAS-dependent transcription in HOS osteosarcoma cells. Our studies from normal osteoblasts shown in Figure 5 indicate that both ISRE and GAS-dependent luciferase activities are not altered in primary HOB cells after transient expression of ISRE-and GAS-luciferase plasmid constructs followed by treatment of 2-ME indicating that 2-ME treatment does not affect ISRE- and GAS-dependent transcriptions in normal osteoblasts.

2-ME effect on IFN-regulated eukaryotic initiation factor (eIF)-2α
To determine the effect of 2-ME on eIF-2α, the effector of IFN-regulated anti-proliferative and anti-tumor signals we have investigated the protein extracts from vehicle and 2-ME-treated osteosarcoma cells. Our results indicate that the eIF-2α phosphorylation increases in the presence of 2-ME treatment. 2-ME treatment increases eIF-2α phosphorylation after 16 h by 15-, 4, 2- and 2-fold in MG63, 143B, KHOS and HOS cells compared to vehicle (Figure 6A &6B) [18]. 2-ME treatment does not affect eIF-2α and phosphor eIF-2α in HOB cells (Figure 6A). Our results show that the levels of
non-phosphorylated eIF-2α and the control glyceraldehyde 3-phosphate dehydrogenase (GAPDH) are not affected in the presence of vehicle control and 2-ME-treatment (Figure 6A).

Regulation of eIF-2α protein in osteosarcoma patients
Several experimental studies and clinical trials show that osteosarcoma responds to IFN therapy. To investigate whether IFN pathway is regulated in osteosarcoma, we...
2-ME effect on IFN gene promoter activity in Osteosarcoma Cells. MG63 and 143B cells transiently transfected with pBlueIFNluciferase were treated with Veh and 2-ME (10 μM) for 24 hrs and the luciferase reporter activity was analyzed. Values are the mean + SE (n = 6 replicate cultures).

Figure 3 2-ME effect on ISRE-Luciferase Activities in Osteosarcoma Cells. MG63 and 143B cells transiently transfected with ISRE-luciferase were treated with Veh and 2-ME (10 μM) for 24 hrs and the luciferase reporter activity was analyzed. Values are the mean + SE (n = 6 replicate cultures) * P < 0.05 vs Veh.
Figure 4 2-ME effect on GAS-Luciferase Activities in Osteosarcoma Cells. Cells transiently transfected with GAS-luciferase were treated with Veh and 2-ME (10 μM) for 24 hrs and the luciferase reporter activity was analyzed. Values are the mean ± SE (n = 6 replicate cultures) *P < 0.05 vs Veh.

Figure 5 2-ME effect on GAS- and ISRE-activities in normal osteoblasts. HOB cells transiently transfected with GAS- and ISRE-luciferase were treated with Veh and 2-ME (10 μM) for 24 hrs and the luciferase reporter activity was analyzed. Values are the mean ± SE (n = 6 replicate cultures).
have analyzed the regulation of eIF-2α protein. Figure 6 shows the levels of phosphorylated and total levels of eIF-2α from four representative normal control muscle and osteosarcoma tissues from 15 patients. The representative blot from four tissues is shown in Figure 6C. Quantitation of signals from protein analysis by western blot hybridization shows that ratio of peIF-2α to eIF-2α decreases from 3- to 42-fold in 11 of 15 osteosarcoma tissues analyzed, demonstrating an increased phosphorylation of eIF-2α in normal compared to tumor (Figure 6D). The phosphorylation of eIF-2α is increased by 3-fold and 9-fold in 2 tumor tissues compared to normal and does not alter in 2 patients analyzed. Whereas, the levels of non-phosphorylated eIF-2α and the control glyceraldehyde 3-phosphate dehydrogenase (GAPDH) are not affected in control and tumor tissues (Figure 6C).

Discussion
Unlike the parent compound, 17β-estradiol, the metabolite 2-ME shows anti-growth effects and functions as a potential therapeutic agent in several types of cancer. We have previously shown that 2-ME induces cell death in osteosarcoma cells but not in normal osteoblasts [4,5]. In this report, we demonstrate that 2-ME regulates IFN pathway in a number of osteosarcoma cell lines. 2-ME induces IFN gene promoter activity, expression, and IFN-dependent transcriptional activities in low tumorigenic MG63 and high tumorigenic 143B osteosarcoma cells. 2-ME-dependent effects on IFN genes and pathways are specific to osteosarcoma cells and are associated with anti-proliferative effects. Whereas 2-ME does not influence IFN and IFN-dependent pathways in normal HOB cells which have been previously shown to be resistant to the anti-growth activities of 2-ME [5]. Our results also show that the eIF-2α protein and the downstream effectors of IFN pathway are regulated by 2-ME treatment in several osteosarcoma cell lines. In addition, eIF-2α phosphorylation is decreased in osteosarcoma tumor patients compared to normal. Our results suggest that IFN pathway is involved in osteosarcoma growth and regulation.

It has been reported earlier that 2-ME-mediated cell death is accompanied by increases in IFNβ mRNA levels in low metastatic MG63 osteosarcoma cells [5]. Current investigation shows that 2-ME induces type I IFN (α
and β) mRNA levels in low and high tumorigenic osteosarcoma cells. In MG63 cells, the mRNA levels increase at 16 and 24 h. Whereas, in 2-ME-treated 143B cells, IFNα increases at 16 h and IFNβ mRNA increases at 8 and 24 h. While this biphasic induction needs to be studied further, the late induction may be due to secondary responses and to transcription factors that may be activated during early response. The induction of mRNA appears to be due to the induction of gene promoter activity. 2-ME-mediated induction of IFN promoter suggests that 2-ME might recruit transcription factors (proteins) that could directly bind to regulatory elements on the IFN promoter. Previous studies show that (nuclear factor kappa B) NFκB, (interferon regulatory factor) IRF-1 and P53 proteins directly bind to IFN gene sequences and induce transcription. 2-ME-mediated anti-tumor effects in osteosarcoma cells and in several other systems involve the induction of P53 [6,19]. Further work is needed to determine whether P53 or other protein transcription factors are involved in these biological effects of 2-ME and contribute to 2-ME-stimulated responses and IFN promoter activities.

IFN-mediated transcriptional activation and signaling has been well studied by several investigators using various model systems [9]. IFN actions trigger a cascade of events leading to ISRE and GAS dependent transcriptional events [20,21]. While ISRE effect is mainly induced through the type I IFNs, IFNα and IFNβ [22], the GAS effects are induced by type II IFN family member, IFNγ [23]. Our results show that 2-ME treatment increased transcription of ISRE- dependent transcription in MG63, 143B, KHOS and HOS osteosarcoma cells. Similarly, GAS-dependent transcription is increased in MG63, 143 and KHOS osteosarcoma cells but not in HOS cells. This differential response could be due in part to the differences in cell origin and the genetic heterogeneity of osteosarcoma. GAS and ISRE activations are due to specific activation of JAK/STAT family members and formation of dimeric complexes of STAT family members in cytoplasm and translocation into nucleus [9,20,24]. However, detailed investigations are required to identify the nature of hetero- and homodimers that might be forming in 2-ME-treated cells and contributing to the activation of ISRE and GAS elements.

2-ME treatment does not affect IFN promoter activity or gene expression and IFN-regulated pathways in normal HOB cells. We have previously demonstrated that 2-ME induces anti-growth activities in several osteosarcoma cell lines but not in normal primary HOB cells [5]. Current studies suggest that there is an association between 2-ME-induced anti-proliferative effects and the induction of IFN pathways in 2-ME-treated osteosarcoma cells.

IFN was approved nearly three decades ago for clinical applications. IFN-α2 remains a mainstay of treatment for viral infections and certain forms of cancer including osteosarcoma. Studies have shown that the protein products of IFN, the couple of hundred IFN stimulated genes (ISGs), underlie the biological and clinical effects of IFNs [9,11]. They provide fundamental cellular defense mechanisms against viral infections and cancer. Studies from other groups have shown that co-treatment of IFN improves the anti-tumor effects of chemotherapeutic agents such as doxorubicin and etoposide [15]. The European American oncology study group (EURAMOS) is investigating the effect of IFN as a follow up therapy in patients who have undergone conventional chemotherapy[10,12]. Furthermore, IFN has been shown to increase the chemotherapy sensitivity of osteosarcoma cell lines [25]. Although additional work is warranted to delineate these molecular pathways in 2-ME treated osteosarcoma cells, our findings point out that IFN signaling could play important role in the control of osteosarcoma.

IFN-regulated anti-tumor mechanisms are mediated by eukaryotic initiation factor (eIF)-2, and through the down-regulation of protein synthesis [26,27]. EIF-2 mediated mechanism has been well documented in IFN-treated cells and in several other cancer models [27]. EIF-2 forms a ternary complex with GTP and MET-tRNA and delivers the initiation factor tRNA to the ribosomal site of protein synthesis [26,28-30]. The eIF-2 is discharged and released as a complex with GDP. This GDP should be replaced with GTP in order for eIF-2 to form a new ternary complex and trigger a new set of translation initiation. The phosphorylated form of eIF-2 is not able to trigger initiation resulting in the inhibition of protein synthesis [26-28]. Our work from previously published reports and from current studies indicate that 2-ME treatment results in the phosphorylation of eIF-2α protein in vitro. The regulation is specific to anti-growth activities of 2-ME since 2-ME does not appear to regulate eIF-2α in HOB cells. Our analyses of tissue specimens from patients show decreased levels of the phosphorylated form of eIF-2α protein in osteosarcoma tissues compared to normal (Table 1). The disease specific regulation was observed in 11 out of 15 specimens. The eIF-2α phosphorylation is associated with osteosarcoma independent of organ and histology subtype as summarized in Table 1. This raises the possibility that a cause for tumor progression could be the decreased eIF-2α phosphorylation which eventually results in decreased inhibition of protein synthesis and apoptosis in tumor cells. Additional data involving a large number of tissues would be necessary to conclude whether the apparent difference in phosphorylation reflects the apparent differences in growth regulation between
normal and tumor tissues. These observations further corroborate our findings that exposure to 2-ME leads to increased phosphorylation of eIF-2α resulting in increased apoptotic and anti-tumor effects due to the inhibition of protein synthesis in osteosarcoma cells [18]. These investigations point out that decreased IFN-signaling could be potentially associated with the disease state in osteosarcoma tissues. Recent studies show that IFN inhibitory activity in osteosarcoma patients could be an important factor that contributes to tumor progression. Inhibition of IFN pathways could lead to increased susceptibility to disease and progression of disease to metastatic stages [31]. These findings and our current results emphasize that understanding of IFN signaling could help diagnose and provide optimal therapy in osteosarcoma patients.

Conclusions
In conclusion, we have shown that IFN signaling is associated with osteosarcoma regulation and 2-ME-mediated cell death in osteosarcoma cells. Hence, upregulation of IFN pathway could be an effective strategy for controlling osteosarcoma.

Acknowledgements
This work was supported by Mayo Clinic Cancer Center Bridging to Success Award (Fraternal order of Eagles) and the Mayo Clinic.

Author details
1 Department of Orthopedics, College of Medicine, Mayo Clinic, 3-69 Medical Sciences, Rochester, MN 55906, USA. 2 Paracelsus Medical University, Salzburg 5020, Austria. 3 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.

Authors' contributions
FW carried out the transfections and reporter assays. CY and RG carried out the cell treatment and western blot analysis. MZ performed the RNA analysis. KS carried out the reporter assays, western blot analysis, coordinated the study and performed the statistical analysis. SR coordinated the patient tissue collection and data analysis. MJY contributed to the study design and clinical data analysis. AM designed the experiments, coordinated the study, interpreted the results, and drafted the manuscript. All authors read and approved the final manuscript.

Competing interests
Mayo Clinic has a user patent on 2-methoxyestradiol in applications involving bone cancer.

Received: 23 August 2011 Accepted: 19 March 2012 Published: 19 March 2012

References
1. O’Reilly R, Cheung NK, Bowman L, Castle V, Helfer F, Kapoor N, Ketzel M, Lindley K, Shamberger R, Tubergen D: NCCN pediatric neuroblastoma practice guidelines. The National Comprehensive Cancer Network. Oncology (Huntingt) 1996, 10(12):1813-1822.
2. Ward WG, Mikaelian K, Dorey F, Mira JM, Sassoon A, Holmes EC, Elber R, Eckardt JJ: Pulmonary metastases of stage IIIB extremity osteosarcoma and subsequent pulmonary metastases. J Clin Oncol 1994, 12(9):1849-1858.
3. Fotis T, Zhang Y, Pepper MS, Adlercreuz H, Montesano R, Nawroth PP, Schweigerer L: The endogenous oestrogen metabolite 2-methoxyestradiol inhibits angiogenesis and suppresses tumour growth. Nature 1994, 368(6468):237-239.
4. Benedikt MB, Mahlum EW, Shogren KL, Subramaniam M, Speilsberg TC, Yazzemski MJ, Maran A: 2-methoxyestradiol-mediated anti-tumor effect increases osteoprotegerin expression in osteosarcoma cells. JCellBiochem 2010, 109(5):950-956.
5. Maran A, Zeng M, Kennedy AM, Sibonga JD, Rickard DJ, Speilsberg TC, Turner RT: 2-Methoxyestradiol Induces Interferon Gene Expression and Apoptosis in Osteosarcoma Cells. BONE 2002, 30(2):393-398.
6. Pribluda VS, Gubisch ER Jr, Lavallee TM, Treston A, Swartz GM, Green SJ: 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Met Rev 2000, 19(1-2):173-179.
7. Rickert JL, Chen Z, Yang XP, Pribluda VS, Swartz GM, Waes C: 2-Methoxyestradiol Inhibits Hypoxia-Inducible Fator 1a, Tumor Growth, and Angiogenesis and Augments Paclitaxel Efficacy in Head and Neck Squamous Cell Carcinoma, Clin Cancer Res 2004, 10(10):3665-3673.
8. Schumacher G, Kataoka M, Roth JA, Mukhopadhyay T: Potent antitumor activity of 2-methoxyestradiol in human pancreatic cancer cell lines. Clin Cancer Res 1999, 5(3):493-499.
9. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD: How cells respond to interferons. Ann Rev Biochem 1998, 67:227-264.
10. Strander H: Interferons and osteosarcoma. Cytokine & Growth Factor Rev 2007, 18(5-6):373-385.
11. Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, Borden EC: Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003, 8(3):237-249.
12. Whelan J, Patterson D, Perisogou M, Bielack S, Marina N, Smeland S, Bernstein M: The role of interferons in the treatment of osteosarcoma. Pediatr Blood Cancer 2010, 54(3):350-354.
13. Carle D, Bielack SS: Current strategies of chemotherapy in osteosarcoma. International orthopaedics, 2006, 30(6):445-451.
14. Glasgow LA, Kern ER: Effect of interferon administration on pulmonary osteogenic sarcomas in an experimental murine model. Journal of the National Cancer Institute 1981, 67(1):207-212.
15. Jia SF, An T, Worth L, Kleinerman ES: Interferon-alpha enhances the sensitivity of human osteosarcoma cells to etoposide. J Interferon Cytokine Res 1999, 19(6):617-624.
16. Jia SF, Kleinerman ES: Antitumor activity of TNF-alpha, IL-1, and IFN-gamma against three human osteosarcoma cell lines. Lymphokine Cytokine Res 1991, 10(4):281-284.
17. Robey PG, Termine JD: Human bone cells in vitro. Calcified tissue international 1985, 37(5):453-460.
18. Shogren KL, Turner RT, Yaszemski MJ, Maran A: Double-stranded RNA-dependent protein kinase is involved in 2-methoxyestradiol-mediated cell death of osteosarcoma cells. J Bone Miner Res 2007, 22(1):29-36.
19. Maran A, Shogren KL, Benedikt M, Sarkar G, Turner RT, Yaszemski MJ: 2-methoxyestradiol-induced cell death in osteosarcoma cells is preceded by cell cycle arrest. J Cell Biochem. 2008, 104:1937-1945.
20. Wierszy J, Szwetykowska-Kulinska Z, Bluyssen HA: STAT activation and differential complex formation dictate selectivity of interferon responses. Acta Biochim Pol 2007, 54(1):27-38.
21. Tsukahara T, Kim S, Taylor MW: REFINEMENT: a search framework for the identification of interferon-responsive elements in DNA sequences-a case study with ISRE and GAS. Comput Biol Chem 2006, 30(2):134-147.
22. Shuai K, Horvath CM, Huang LH, Qureshi SA, Cowburn D, Darrell II Jr: Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell 1994, 76(5):821-828.
23. Decker T, Kavari P, Meinke A: GAS elements: a few nucleotides with a major impact on cytokine-induced gene expression. J Interferon Cytokine Res 1997, 17(3):121-134.
24. Sikorski K, Chmielewski S, Przybyl B, Heermann U, Wesoły J, Baumann M, Bluyssen HA: STAT1-mediated signal integration between IFNgamma and LPS leads to increased EC and SMC activation and monocyte adhesion. Am J Physiol Cell Physiol 2011, 300(6):C1337-C1344.
25. Yuan XW, Zhu XF, Huang XF, Sheng PY, He AS, Yang ZB, Deng R, Feng GK, Luow WM: Interferon-alpha enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin by p53-dependent apoptosis. Acta Pharmacol Sin 2007, 28(11):1835-1841.
26. Balachandran S, Barber GN: PKR in innate immunity, cancer, and viral oncolysis. Methods Mol Biol 2007, 383:277-301.
27. Clemens MJ: Targets and mechanisms for the regulation of translation in malignant transformation. Oncogene 2004, 23(18):3180-3188.
28. Wek RC, Jiang HY, Anthony TG: Coping with stress: eIF2 kinases and translational control. Biochem Soc Trans 2006, 34(Pt 1):7-11.
29. Holcik M, Sonenberg N: Translational control in stress and apoptosis. Nat Rev Mol Cell Biol 2005, 6(4):318-327.
30. Gale M Jr, Tan SL: Karze MG: Translational control of viral gene expression in eukaryotes. Microbiol Mol Biol Rev 2000, 64(2):239-280.
31. Kubo T, Shimose S, Matsu T, Fujimori J, Arthiro K, Ochi M: Interferon-alpha/beta receptor as a prognostic marker in osteosarcoma. J Bone Joint Surg Am 2011, 93(6):519-526.

Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/12/93/prepub

doi:10.1186/1471-2407-12-93
Cite this article as: Wimbauer et al.: Regulation of interferon pathway in 2-methoxyestradiol-treated osteosarcoma cells. BMC Cancer 2012, 12:93.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit